Evaluation of a panel of therapeutic antibody clinical candidates for efficacy against SARS-CoV-2 in Syrian hamsters.

"Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper."

"Funding This project has been funded in whole or in part with federal funds from the National Institute of Allergy and Infectious Diseases (NIAID, National Institutes of Health (NIH), U.S. Department of Health and Human Services (DHHS), under Contract No. HHSN272201800013C. Y.C., D.L.P, S.D., E.K., R.B., L.H., D.D., R.H., N.V., and M.R.H., performed this work as employees of Laulima Government Solutions, LLC. Subcontractors to Laulima Government Solutions, LLC who performed this work are: J.L., A.H., and E.P., all employees of Tunnell Government Services, Inc. The content of this publication does not necessarily reflect the views or policies of the DHHS or of the institutions and companies with which the authors are affiliated. Opinions, interpretations, conclusions, and recommendations are those of the author and are not necessarily endorsed by the U.S. Army. The animal study protocol at the IRF was reviewed and approved by the NIH NIAID DCR IRF-Frederick Institutional Animal Care and Use Committee (IACUC) and the animal study at USAMRIID was reviewed and approved by the USAMRIID IACUC in compliance with all applicable federal regulations governing the protection of animals and research. The facilities where this research was conducted adhere to principles stated in the Guide for the Care and Use of Laboratory Animals, National Research Council, 2011."